Skip to main content
Terug
MEDOF logo

Medios AG

Datakwaliteit: 100%
Overbought
MEDOF
OTC Healthcare Medical - Distribution
€ 50,00
€ 0,00 (0,00%)
Marktkapitalisatie: 1,23B
Dagbereik
€ 13,64 € 50,00
52-Weeksbereik
€ 13,64 € 50,00
Volume
2.000
50D / 200D Gem.
€ 50,00 / € 50,00
Vorige Slotkoers
€ 50,00

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 97,7 0,4
P/B 2,4 2,9
ROE % 2,6 3,7
Net Margin % 0,7 3,9
Rev Growth 5Y % 31,7 10,0
D/E 0,5 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2028 € 0,00
€ 0,00 – € 0,00
 2,3 B 0
FY2027 € 1,69
€ 1,66 – € 1,73
 2,2 B 1
FY2026 € 1,38
€ 1,36 – € 1,41
 2,1 B 1

Belangrijkste Punten

Revenue grew 31,67% annually over 5 years — strong growth
Earnings declined -33,29% over the past year
ROE of 2,56% is below average
Debt/Equity of 0,47 — conservative balance sheet
Generating 67,36M in free cash flow
P/E of 97,65 — premium valuation

Groei

Revenue Growth (5Y)
31,67%
Revenue (1Y)5,51%
Earnings (1Y)-33,29%
FCF Growth (3Y)44,95%

Kwaliteit

Return on Equity
2,56%
ROIC3,17%
Net Margin0,67%
Op. Margin1,68%

Veiligheid

Debt / Equity
0,47
Current Ratio2,02
Interest Coverage2,91

Waardering

P/E Ratio
97,65
P/B Ratio2,40
EV/EBITDA42,88
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 5,51% Revenue Growth (3Y) 8,12%
Earnings Growth (1Y) -33,29% Earnings Growth (3Y) -17,26%
Revenue Growth (5Y) 31,67% Earnings Growth (5Y) 22,76%
Profitability
Revenue (TTM) 1,88B Net Income (TTM) 12,55M
ROE 2,56% ROA 1,34%
Gross Margin 8,04% Operating Margin 1,68%
Net Margin 0,67% Free Cash Flow (TTM) 67,36M
ROIC 3,17% FCF Growth (3Y) 44,95%
Safety
Debt / Equity 0,47 Current Ratio 2,02
Interest Coverage 2,91 Dividend Yield 0,00%
Valuation
P/E Ratio 97,65 P/B Ratio 2,40
P/S Ratio 0,65 PEG Ratio -2,65
EV/EBITDA 42,88 Dividend Yield 0,00%
Market Cap 1,23B Enterprise Value 1,36B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 1,88B 1,78B 1,61B 1,36B 626,54M
Net Income 12,55M 18,81M 18,33M 7,40M 5,53M
EPS (Diluted) 0,49 0,79 0,77 0,37 0,35
Gross Profit 151,46M 108,63M 106,87M 68,48M 37,58M
Operating Income 31,67M 31,37M 28,97M 15,26M 9,54M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 934,36M 594,75M 575,96M 524,14M 194,54M
Total Liabilities 424,17M 125,95M 127,91M 129,98M 52,11M
Shareholders' Equity 510,19M 468,81M 448,05M 394,16M 142,43M
Total Debt 238,37M 17,15M 17,63M 49,71M 19,23M
Cash & Equivalents 106,00M 71,04M 79,21M 168,43M 19,79M
Current Assets 345,82M 269,19M 250,01M 300,67M 136,30M
Current Liabilities 171,07M 83,23M 82,06M 93,77M 30,63M

Strategiescores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#664 of 1024
38
Growth Price/Sales Ratio Focus (Ken Fisher)
#412 of 616
24

Recente Activiteit

Ingestapt Cash Flow Compounder
Mar 24, 2026
Ingestapt Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026